-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, driven by multiple forces such as policies and capital, China's pharmaceutical industry has entered a stage of rapid development.
Many places have also regarded this industry as a new economic growth point and have continued to increase their layout
.
In the context of increasing policy support for pharmaceutical innovation, the capital market for innovative drugs has continued to rise, and many pharmaceutical companies have also begun to compete to introduce new drugs to enhance their innovation capabilities
.
Recently, Tasly Pharmaceuticals Group Co.
, Ltd.
announced that its subsidiary Tasly Bio-Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Tasly Biological") has obtained the exclusive license of Sutro Biopharma (hereinafter referred to as "Sutro") in the United States, in the region (i.
e.
, Mainland China, Hong Kong).
(And Macau Special Administrative Region, Taiwan) exclusively developed, registered, and commercialized an antibody-conjugated drug targeting folate receptor α (FRα) (hereinafter referred to as "STRO-002").
STRO-002 is currently targeting ovaries in Europe and the United States.
Clinical research on cancer and endometrial cancer
.
According to the license agreement, Tasly Bio will pay Sutro US$40 million in advance and potentially up to US$345 million in development and commercialization milestone payments, as well as an agreed percentage of sales commissions
.
In addition to Tasly, BeiGene also announced on December 14 that it had signed a cooperation with Wei Li Zhibo, from the latter to introduce a global research and development and production license for the LAG-3 antibody LBL-007, and Exclusive commercialization rights outside of China
.
According to the agreement, Wei Li Zhibo will receive an advance payment of 30 million US dollars, and after reaching clinical development, drug regulatory approval and sales milestones, it will be eligible to receive a total transaction amount of up to 742 million US dollars, and double digits in authorized regions Graded sales royalties
.
The industry believes that the above companies are actually just a microcosm of the introduction of new drugs by domestic pharmaceutical companies
.
From an overall point of view, license in has clearly become one of the rapid development methods for domestic innovative pharmaceutical companies
.
It’s worth mentioning that under the background that domestic pharmaceutical companies are accelerating the introduction of new drugs, their results have begun to show up.
.
Take Huadong Medicine as an example, earlier it introduced a FRα ADC IMGN853 (Mirvetuximab Soravtansine)
.
On December 1, Huadong Medicine and its partner ImmunoGen jointly announced that the key US single-arm clinical trial (SORAYA trial) of IMGN853 has reached the primary research end point.
It is expected to submit a biological product license application (BLA )
.
In addition, it has also initiated phase III clinical trials in China
.
In general, according to the current domestic emphasis on innovative drugs, more and more pharmaceutical companies will introduce new drugs frequently in the future, enrich their product pipelines through the license in (authorized introduction) model, and enhance their innovation capabilities
.
However, at the same time, the industry has also proposed that although the introduction of new drug models can quickly expand the product pipeline, such pharmaceutical companies will also face many tests in the future, including their ability to judge drugs and BD levels, and domestic clinical advancement and sales capabilities.
, And the continuous increase of the country's strict control of counterfeit innovation from the regulatory level
.
Many places have also regarded this industry as a new economic growth point and have continued to increase their layout
.
In the context of increasing policy support for pharmaceutical innovation, the capital market for innovative drugs has continued to rise, and many pharmaceutical companies have also begun to compete to introduce new drugs to enhance their innovation capabilities
.
Recently, Tasly Pharmaceuticals Group Co.
, Ltd.
announced that its subsidiary Tasly Bio-Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Tasly Biological") has obtained the exclusive license of Sutro Biopharma (hereinafter referred to as "Sutro") in the United States, in the region (i.
e.
, Mainland China, Hong Kong).
(And Macau Special Administrative Region, Taiwan) exclusively developed, registered, and commercialized an antibody-conjugated drug targeting folate receptor α (FRα) (hereinafter referred to as "STRO-002").
STRO-002 is currently targeting ovaries in Europe and the United States.
Clinical research on cancer and endometrial cancer
.
According to the license agreement, Tasly Bio will pay Sutro US$40 million in advance and potentially up to US$345 million in development and commercialization milestone payments, as well as an agreed percentage of sales commissions
.
In addition to Tasly, BeiGene also announced on December 14 that it had signed a cooperation with Wei Li Zhibo, from the latter to introduce a global research and development and production license for the LAG-3 antibody LBL-007, and Exclusive commercialization rights outside of China
.
According to the agreement, Wei Li Zhibo will receive an advance payment of 30 million US dollars, and after reaching clinical development, drug regulatory approval and sales milestones, it will be eligible to receive a total transaction amount of up to 742 million US dollars, and double digits in authorized regions Graded sales royalties
.
The industry believes that the above companies are actually just a microcosm of the introduction of new drugs by domestic pharmaceutical companies
.
From an overall point of view, license in has clearly become one of the rapid development methods for domestic innovative pharmaceutical companies
.
It’s worth mentioning that under the background that domestic pharmaceutical companies are accelerating the introduction of new drugs, their results have begun to show up.
.
Take Huadong Medicine as an example, earlier it introduced a FRα ADC IMGN853 (Mirvetuximab Soravtansine)
.
On December 1, Huadong Medicine and its partner ImmunoGen jointly announced that the key US single-arm clinical trial (SORAYA trial) of IMGN853 has reached the primary research end point.
It is expected to submit a biological product license application (BLA )
.
In addition, it has also initiated phase III clinical trials in China
.
In general, according to the current domestic emphasis on innovative drugs, more and more pharmaceutical companies will introduce new drugs frequently in the future, enrich their product pipelines through the license in (authorized introduction) model, and enhance their innovation capabilities
.
However, at the same time, the industry has also proposed that although the introduction of new drug models can quickly expand the product pipeline, such pharmaceutical companies will also face many tests in the future, including their ability to judge drugs and BD levels, and domestic clinical advancement and sales capabilities.
, And the continuous increase of the country's strict control of counterfeit innovation from the regulatory level
.
